m6A Target Gene Information

General Information of the m6A Target Gene (ID: M6ATAR00071)
Target Name hsa_circ_0087293 (SORE)
Synonyms
hsa-circ-0087293
    Click to Show/Hide
Gene Name hsa_circ_0087293
Full List of m6A Methylation Regulator of This Target Gene and Corresponding Disease/Drug Response(s)
hsa_circ_0087293 can be regulated by the following regulator(s), and cause disease/drug response(s). You can browse detail information of regulator(s) or disease/drug response(s).
Browse Disease
Browse Drug
Liver cancer [ICD-11: 2C12]
 Disease Info 
In total 1 item(s) under this disease
Experiment 1 Reporting the m6A-centered Disease Response []
Response Summary N6-methyladenosine-modified hsa_circ_0087293 (SORE) sequestered miR-103a-2-5p and miR-660-3p by acting as a microRNA sponge, thereby competitively activating the Wnt/beta-catenin pathway and inducing sorafenib resistance in hepatocellular carcinoma.
Responsed Disease Hepatocellular carcinoma [ICD-11: 2C12.02]
Responsed Drug Sorafenib Approved
 Drug Info 
Cell Process Cell apoptosis
In-vitro Model ()
()
()
()
In-vivo Model The first CDX generation was constructed in 4-6 week-old male BALB/c nude mice and treated with sorafenib (30 mg/kg daily, oral gavage). Twelve weeks later, the most resistant xenograft was disaggregated and implanted subcutaneously into 4-6 week-old BALB/c nude mice as the second SR-CDX. Four weeks after implantation, the second SR-CDX mice were treated with sorafenib (30 mg/kg daily, oral gavage) and locally injected with sh-circRNA-SORE lentivirus or its negative control (twice a week for 2 weeks).
Sorafenib [Approved]
 Drug Info 
In total 1 item(s) under this drug
Experiment 1 Reporting the m6A-centered Drug Response []
Response Summary N6-methyladenosine-modified hsa_circ_0087293 (SORE) sequestered miR-103a-2-5p and miR-660-3p by acting as a microRNA sponge, thereby competitively activating the Wnt/beta-catenin pathway and inducing sorafenib resistance in hepatocellular carcinoma.
Responsed Disease Hepatocellular carcinoma ICD-11: 2C12.02
 Disease Info 
Cell Process Cell apoptosis
In-vitro Model ()
()
()
()
In-vivo Model The first CDX generation was constructed in 4-6 week-old male BALB/c nude mice and treated with sorafenib (30 mg/kg daily, oral gavage). Twelve weeks later, the most resistant xenograft was disaggregated and implanted subcutaneously into 4-6 week-old BALB/c nude mice as the second SR-CDX. Four weeks after implantation, the second SR-CDX mice were treated with sorafenib (30 mg/kg daily, oral gavage) and locally injected with sh-circRNA-SORE lentivirus or its negative control (twice a week for 2 weeks).